Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. The company's proprietary platform technology called the Transport Vehicle enabled programs include tividenofusp alfa (DNL310, ETV:IDS) for mucopolysaccharidosis II (MPS II or Hunter syndrome); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (“ALS”). Its pipeline products include Iduronate 2-sulfatase, LRRK2, Progranulin, Sulfamidase, Alpha-L-iduronidase, eIF2B and RIPK1 (Peripheral). The company's pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, lysosomal storage disorder disease, neurodegeneration, amyotrophic lateral sclerosis and other indications. Denali Therapeutics is headquartered in San Francisco, California, the US.
Denali Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Lysosomal Function |
LRRK2: Parkinson's Disease |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Denali Therapeutics Inc | Eli Lilly and Co | Biogen Inc | Ionis Pharmaceuticals Inc | Prothena Corp Plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | Ireland |
City | South San Francisco | Indianapolis | Cambridge | Carlsbad | Dublin |
State/Province | California | Indiana | Massachusetts | California | - |
No. of Employees | 375 | 43,000 | 7,570 | 927 | 173 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Vicki Sato | Chairman | Executive Board | 2016 | 74 |
Ryan J. Watts | Chief Executive Officer; President; Director | Executive Board | 2015 | 47 |
Cindy Dunkle | Chief People Officer | Senior Management | - | - |
Carole Ho | Chief Medical Officer; Head - Development | Senior Management | 2015 | 50 |
Joe Lewcock | Chief Scientific Officer; Head - Discovery | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer